Vaccines are the most effective means of preventing and controlling the spread of the virus, which is also crucial to China’s eventual victory over the epidemic.
Sinopharm group disclosed on May 29 that the clinical data of more than 2,000 cases showed that the safety and efficacy of the vaccine had been fully verified, and the incidence and degree of adverse reactions were far lower than those of all kinds of vaccines on the market.
Sinopharmaceutical group China bio is a biological blood product enterprise with the longest history, the most complete products, the largest scale and the strongest comprehensive strength in China and even in Asia.
At present, China produces more than 50 kinds of biological vaccines annually, with an annual capacity of over 700 million doses, and supplies more than 80% of China’s national immunization program vaccines.
Since the outbreak, national medicine group, the China’s biological vaccine research and development as the pinnacle of researches, in the whole virus inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccine, nucleic acid vaccine and attenuated influenza virus vector vaccine on five technical route, through full demonstration, finally determine the controllable inactivated vaccine technology mature standards, with large-scale production and widespread use of experience and conditions.
Currently, China has achieved initial results in the development of inactivated vaccines.
“Wuhan institute of biological products on April 12, Beijing institute of biological products on April 27, the state food and drug administration of the new coronavirus inactivated vaccine clinical approval, now have entered phase ii clinical.
Chairman of Chinese biology Yang xiaoming introduces, present clinical data of more than 2000 cases shows, the antibody that the subject produces has reached resistance novel coronavirus level completely, positive rate of novel coronavirus antibody reached 100%.
Whether the vaccine is safe and effective is one of the biggest concerns of the public.
Yang xiaoming further explained that according to the data obtained so far, the safety of the vaccine was very good, and no serious adverse reactions occurred in any subjects.
From the effectiveness point of view, the antibody level has two main indicators, namely the antibody positive conversion rate and the average antibody level.
At present, the clinical results show that the two effectiveness indicators are also ideal.
The reporter understands, antibody positive turns rate namely after vaccinating vaccine, the proportion that human body produces corresponding antibody, this also is regarded as an important index of immune success rate.
Yang xiaoming said that in order to improve the effectiveness of the inactivated coronavirus vaccine, China has conducted animal experiments on seven different species and strains, including mice, rabbits and monkeys, as well as a variety of other physical and chemical indicators, so as to ensure that the vaccine can be developed safely and effectively.
The trial is divided into three phases.
The clinical trial program adopts the method of age sequence and dose sequence. The clinical study can only be put on the market after the completion of the technical review and evaluation by the food and drug administration and the completion of the clinical on-site verification, production on-site verification, quality review by the institute of quality inspection and GMP certification.
At present, the relevant links have been transformed from series to parallel to accelerate the clinical research. The vaccine is expected to be ready for phase I to III clinical trials until the market, which is expected to be completed by the end of this year or early next year at the earliest.